tradingkey.logo

Impact Biomedical Inc

IBO
查看詳細走勢圖
0.544USD
-0.021-3.70%
收盤 03/30, 16:00美東報價延遲15分鐘
6.25M總市值
虧損本益比TTM

Impact Biomedical Inc

0.544
-0.021-3.70%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-3.70%

5天

-30.28%

1月

+24.93%

6月

-17.32%

今年開始到現在

+7.68%

1年

-64.22%

查看詳細走勢圖

TradingKey Impact Biomedical Inc股票評分

單位: USD 更新時間: 2026-03-27

操作建議

Impact Biomedical Inc當前公司基本面數據相對謹慎,最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名217/391位。機構持股佔比非常高,中期看,股價處於上升通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Impact Biomedical Inc評分

相關信息

行業排名
217 / 391
全市場排名
456 / 4542
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Impact Biomedical Inc亮點

亮點風險
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
業績增長期
公司處於發展階段,最新年度總收入32.00K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入32.00K美元
估值低估
公司最新PE估值-1.53,處於3年歷史低位
機構加倉
最新機構持股1.23M股,環比增加31.56%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉814.88K股

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Impact Biomedical Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Impact Biomedical Inc簡介

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
公司代碼IBO
公司Impact Biomedical Inc
CEOHeuszel (Frank D)
網址https://www.impactbiomedinc.com/
KeyAI